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 2 
Abstract 23 
Burkholderia pseudomallei causes significant global morbidity and mortality, 24 
with the highest disease burden in parts of Asia where culture-based 25 
diagnosis is often not available. We prospectively evaluated the Active 26 
Melioidosis Detect (AMD, InBios International, USA) lateral flow immunoassay 27 
(LFI) for rapid detection of B. pseudomallei in turbid blood cultures, pus, 28 
sputum, sterile fluid, urine, and sera. Performance was compared to B. 29 
pseudomallei detection using monoclonal antibody latex agglutination (LA) 30 
and immunofluorescence assays (IFA), with culture as the gold standard. 31 
AMD was 99% (99/100; 94.6 – 100%) sensitive and 100% (308/308; 98.8-32 
100%) specific on turbid blood culture bottles, with no difference to LA or IFA. 33 
AMD specificity was 100% on pus (122/122; 97.0-100%), sputum (20/20; 34 
83.2-100%), and sterile fluid (44/44; 92 – 100%). Sensitivity on these samples 35 
was: pus 47.1% (8/17; 23.0 – 72.2%), sputum 33.3% (1/3; 0.84 – 90.6%), and 36 
sterile fluid 0% (0/2; 0 – 84.2%). Urine AMD had a positive predictive value of 37 
94% (32/34; 79.7 – 98.5%) for diagnosing melioidosis in our cohort. AMD 38 
sensitivity on stored sera, collected prospectively from melioidosis cases 39 
during this study, was 13.9% (5/36; 4.7% - 29.5%) when compared to blood 40 
culture samples taken on the same day. In conclusion, the AMD is an 41 
excellent tool for rapid diagnosis of melioidosis from turbid blood cultures, and 42 
maintains specificity across all sample types. It is a promising tool for urinary 43 
antigen detection, which could revolutionise diagnosis of melioidosis in 44 
resource-limited settings. Further work is required to improve sensitivity on 45 
non-blood culture samples.   46 
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 3 
Introduction 47 
Burkholderia pseudomallei is a saprophytic bacterium causing melioidosis, a 48 
disease with diverse clinical manifestations including fulminant septicaemia, 49 
pneumonia, meningo-encephalitis, abscess formation, septic arthritis and 50 
more indolent cutaneous presentations (1).  The global burden of melioidosis 51 
has been estimated at 165,000 cases/year with 89,000 fatalities (2).  The 52 
highest known burden of disease is in south and southeast Asia where case 53 
fatality rates reach around 40% (3), and even in countries with advanced 54 
healthcare systems such as Australia, mortality reaches 14% (4). In the Lao 55 
People’s Democratic Republic (Laos), increasing numbers of cases have 56 
been recognized since the disease was first diagnosed in 1999 (5), and more 57 
than 100 cases of culture-confirmed melioidosis are now being detected at 58 
Mahosot Hospital Microbiology Laboratory each year with peak incidence 59 
during the rainy season (6). 60 
 61 
Culture is currently the gold standard diagnostic test for melioidosis with 100% 62 
specificity but an estimated sensitivity of only 60% (7). However, culture 63 
confirmation takes a minimum of 48-72hrs (7), requires specific media for 64 
optimal sensitivity in non-sterile samples (8), and laboratory  containment and 65 
expertise often not available in endemic areas. B. pseudomallei is intrinsically 66 
resistant to many antibiotics and melioidosis therefore does not respond to 67 
most agents used for empiric treatment of sepsis, pneumonia and abscesses 68 
in developing countries (9). Therefore, life-saving treatment is often fatally 69 
delayed if a specific diagnosis cannot be confirmed. Simple, rapid diagnostic 70 
tests for melioidosis for use directly on clinical samples are needed, not only 71 
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 4 
for improving patient outcomes but also to improve epidemiological 72 
surveillance of melioidosis and thereby strengthen public health interventions.  73 
Immunofluorescence to detect B. pseudomallei directly in clinical samples 74 
(10) and latex agglutination for rapid identification of positive cultures (11, 12) 75 
are used in some melioidosis-endemic areas. However, these require 76 
equipment, expertise and reagents that are not widely available. More 77 
recently, an immunochromatographic lateral flow rapid diagnostic test (RDT) 78 
to detect B. pseudomallei extracellular polysaccharide antigen directly in 79 
clinical samples has been developed (Active Melioidosis Detect (AMD), 80 
InBios, USA) (13). The method is simple, rapid (result within 15 minutes), 81 
relatively cheap (estimated $2/test), does not require additional equipment, 82 
and the kit may be stored at room temperature, making it ideal for use in 83 
resource-limited settings. To date this kit has undergone only limited clinical 84 
evaluations (13, 14).  We evaluated the diagnostic performance of AMD on a 85 
variety of clinical samples (including blood culture broths, pus, sterile fluid, 86 
sputum, and urine) over two rainy seasons from patients with suspected and 87 
culture-confirmed melioidosis presenting to Mahosot Hospital, Vientiane, 88 
Laos. 89 
 90 
Results 91 
Analytical sensitivity and specificity 92 
All B. pseudomallei seeded blood cultures were AMD-positive by 12hrs 93 
incubation (Table S1). The lower limit of detection of the AMD was found to be 94 
1.4 x 105 CFU/ml, meaning that it was positive in 3 of 4 seeded blood cultures 95 
before they became visibly turbid and in 4/4 before organisms were 96 
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 5 
detectable by Gram staining of the broth. Centrifugation of blood culture broth 97 
prior to performing AMD did not reduce time to positivity. 98 
 99 
All non-B. pseudomallei reference strains were negative by AMD (Table S2). 100 
Two soil isolates of B. thailandensis and one sputum isolate of B. cepacia 101 
were AMD-positive. All 3 of these isolates were known to give a positive B. 102 
pseudomallei latex agglutination test, probably due to production of a cross-103 
reacting extracellular polysaccharide (15). All four positive control B. 104 
pseudomallei clinical isolates were positive by AMD.  105 
 106 
Prospective evaluation 107 
Between 26th June and 18th December 2014, 89 patients were diagnosed with 108 
melioidosis by culture of B. pseudomallei from at least one sample type 109 
(blood, pus, sputum, sterile fluid, urine, throat swab, wound swab (Figure 110 
S1)). Median age was 45 years (IQR 27-54 years), 55% were male and 20/89 111 
(22.5%) patients died during admission or were discharged moribund. Blood 112 
cultures were received from 85 of these patients (85/89, 96%) of whom 54% 113 
(46/85) were bacteraemic with B. pseudomallei. Of the 43 patients not found 114 
to be bacteraemic, 34 had localized disease whilst 9 had evidence of 115 
multifocal disease. 116 
 117 
Turbid blood cultures 118 
There were 412 turbid blood culture bottles during the study period, of which 4 119 
did not have AMD performed and were therefore excluded. 408 turbid blood 120 
culture bottles from 247 patients were thus included in the analysis. 121 
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 6 
Organisms isolated from the 408 blood cultures are shown in Figure S2. B. 122 
pseudomallei was isolated from 100 bottles (Figure 1a). Overall AMD 123 
sensitivity was 99% (99/100; 94.6 – 100%) and specificity 100% (308/308; 124 
98.8-100%). 252 of these 408 turbid blood culture bottles had Gram-negative 125 
bacilli (GNB) seen on Gram stain and therefore had additional rapid tests 126 
performed: latex agglutination (n=237), immunofluorescence assay (IFA; 127 
n=176) (Figure 1a). Sensitivities and specificities for these tests are given in 128 
Table 1. 166 turbid blood culture samples with GNB seen on microscopy had 129 
all 3 rapid tests performed, with agreement between all 3 rapid tests and 130 
culture in 98.2% (163/166). 1 sample was AMD and latex agglutination 131 
negative but IFA and B. pseudomallei culture positive. 2 samples were scanty 132 
positive by IFA (1-3 bacilli/100 fields) but negative by all other tests.   133 
 134 
Pus 135 
139/150 pus samples received during the study period had AMD performed 136 
and were included in the analysis. B. pseudomallei was cultured from 17/139 137 
samples. 95/139 pus samples also underwent IFA (Figure 1b). AMD was 138 
significantly more specific than IFA (p=0.0006; Table 1). However, all 8 false 139 
positive IFA results were reported as scanty (1-5 bacilli/100 fields).  140 
 141 
Sputum 142 
26 sputa were received during the study period, 3 of which did not have AMD 143 
performed and were excluded. The remaining 23 sputa underwent both AMD 144 
and IFA testing and no significant difference in sensitivity or specificity was 145 
found (Table 1). 3/23 samples were B. pseudomallei culture positive, all 3 of 146 
 o
n
 M
ay 8, 2018 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://jcm.asm.org/
D
ow
nloaded from
 
 7 
which were IFA positive but only 1 of which was AMD positive (Figure 1c). 147 
There were 3 positive IFA tests from culture negative samples, but all were 148 
reported as scanty (1-7 bacilli/100 fields), and 2 of these samples were from 149 
the same patient who, although culture negative for B. pseudomallei, had a 150 
clinical picture compatible with melioidosis and died shortly after transfer to 151 
Thailand for further healthcare. 152 
 153 
Sterile Fluid 154 
Between 10th October and 18th December 2014 50 sterile fluid samples were 155 
received, 46 underwent AMD and were included in the analysis (29 pleural 156 
fluid; 6 joint fluid; 2 pericardial fluid; 9 ascitic fluid). 42/46 also underwent IFA. 157 
B. pseudomallei was isolated from 2 samples (both joint fluid from the same 158 
patient, samples taken 11 days apart); IFA was positive on both these 159 
samples whilst AMD was negative on both (Figure 1d). The sensitivity of IFA 160 
was therefore significantly better than AMD (Table 1) although numbers are 161 
small, and confidence intervals wide.  162 
 163 
Urine 164 
Between 2nd July and 2nd Sept. 2014 249 urine samples were received, AMD 165 
was not performed on 28 and 16 were duplicate specimens, thus 205 were 166 
included in the analysis (Figure 1e.i). 3/205 urine samples were B. 167 
pseudomallei culture positive, 2 of which were AMD positive (sensitivity 66.7% 168 
(9.4 - 99.2%)). The B. pseudomallei culture positive urine sample which was 169 
AMD negative had a low bacterial load with only 1 colony forming unit isolated 170 
from a centrifuged deposit. AMD specificity was 100% (98.2 - 100%; 171 
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 8 
202/202). Organisms isolated in culture from all 205 urines are shown in 172 
Figure S3. 173 
From 3rd September onwards only selected urines were included in the study 174 
(3rd Sept. - 18th December 2014 n=102; 23rd June – 12th Nov. 2015 n=189). 175 
AMD was not performed on 27 samples (2014: 5; 2015: 22 samples), and 23 176 
samples were duplicates and therefore excluded. Thus 241 samples were 177 
included in the analysis. 15/241 urine samples were B. pseudomallei culture 178 
positive, 13/15 of which were AMD positive (Table 1). 21/226 urine culture 179 
negative samples were AMD positive (Figure 1e.ii). Interestingly 19/21 of 180 
these urines came from patients who had melioidosis confirmed by culture 181 
from another site suggesting that these were not “false positive” AMD results 182 
but that the AMD was detecting true B. pseudomallei antigenuria. The positive 183 
predictive value of AMD on urine for correctly diagnosing melioidosis in this 184 
cohort was therefore 94.1% (32/34; 79.7 – 98.5%) with a disease prevalence 185 
of 35.7% (86/241).  186 
Urine samples from melioidosis cases. To further describe B. pseudomallei 187 
antigenuria in our cohort results of urine samples received from the 182 188 
culture-confirmed (from any site) melioidosis cases during the 2014 and 2015 189 
study periods were analyzed further. A urine sample was received from 114 190 
(2014: 57; 2015: 57) of these 182 patients, 20/114 urines were culture positive 191 
for B. pseudomallei (16/20 were AMD positive). 21 of the 94 culture-negative 192 
urines were AMD positive (Table 2). Patients who were urine culture negative 193 
for B. pseudomallei but had disseminated melioidosis were significantly more 194 
likely to be urine AMD positive than those with localized melioidosis (18/61 vs 195 
3/32; p = 0.036). Presence of B. pseudomallei bacteraemia did not increase 196 
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 9 
the likelihood of urine AMD positivity overall (15/49 vs 6/44, p = 0.08), or in 197 
patients with disseminated melioidosis (15/49 vs 3/12, p = 1.0). 198 
 199 
Urine concentration. Due to lack of availability of urine concentrators this was 200 
performed retrospectively on 20 stored urine isolates collected prospectively 201 
between 2nd July and 18th December 2014. All urine samples were from 202 
confirmed melioidosis cases but were AMD negative on neat urine and B. 203 
pseudomallei urine culture negative. 6 of 20 urine samples were AMD positive 204 
after urine concentration. 205 
 206 
Sera 207 
71 stored serum samples from the 89 melioidosis cases diagnosed from 26th 208 
June – 18th December 2014 were available for AMD testing (Figure 1f). 5/71 209 
(7%) samples were AMD positive. Each of these five patients were culture-210 
positive for B. pseudomallei from blood taken on the same day as the serum 211 
sample. Of the patients negative by AMD on sera, 31/66 had been 212 
bacteraemic with B. pseudomallei on the same day as the serum sample was 213 
taken, and a further 9 non-bacteraemic patients had evidence of disseminated 214 
disease. Sera therefore had low sensitivity for diagnosis of melioidosis when 215 
compared with blood culture as the gold standard, 13.9% (5/36; 4.7% - 216 
29.5%). 217 
 218 
Discussion 219 
We evaluated accuracy of the AMD lateral flow immunoassay (LFI) for the 220 
rapid diagnosis of melioidosis directly from clinical samples. The LFI detects 221 
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 10 
extracellular polysaccharide of B. pseudomallei with a limit of detection (LOD) 222 
of 0.2ng/mL (13, 16). On turbid blood cultures the AMD was found to have 223 
excellent analytical and diagnostic sensitivity and specificity, comparable to 224 
both IFA and latex agglutination which were found to have similar 225 
performance characteristics to previous studies (11, 17-19). One turbid blood 226 
culture bottle was AMD and latex agglutination negative but culture positive 227 
for B. pseudomallei. After 24hours further incubation both tests were positive 228 
on the same bottle suggesting that the initial false negative results may reflect 229 
an initial bacterial load lower than the limit of detection for both tests. The high 230 
specificity of the AMD on turbid blood cultures is extremely promising for 231 
deployment to field settings in the tropics, where simple tests such as the 232 
AMD may be performed after a broth incubation step in the absence of 233 
laboratory facilities for Gram stain and culture. A positive AMD result, 234 
potentially obtained as early as 12 hours post blood sampling, could prove 235 
life-saving if antimicrobial treatment is adapted appropriately. 236 
The AMD maintained excellent analytical and diagnostic specificity across all 237 
sample types, even ‘non-sterile’ samples such as sputum and urine, which are 238 
more likely to contain contaminating bacteria (including environmental 239 
Burkholderia spp. in an endemic tropical setting). False positive AMD results 240 
were only seen in our study with environmental Burkholderia strains known to 241 
express a similar extracellular polysaccharide to that detected by the AMD. 242 
Although this may pose a problem when the AMD is used for detection of B. 243 
pseudomallei in environmental samples such as soil (20), in clinical samples it 244 
is rarely likely to be relevant. The finding of AMD reactivity in a clinical strain 245 
of B. cepacia in this study is novel, as previous testing of B. cepacia complex 246 
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 11 
strains had not demonstrated this (unpublished observations, D. AuCoin). 247 
Relatively few sputum samples were included in this study and further work is 248 
needed to investigate how frequently respiratory samples containing non-249 
pseudomallei Burkholderia (for example from patients with cystic fibrosis) may 250 
cause AMD reactivity. However, in our experience such strains are rare and 251 
the majority of B. cepacia isolates do not cross react in this way (data not 252 
shown).   253 
AMD analytical sensitivity was extremely promising, with AMD LOD on broth 254 
cultures better than previous estimates of LOD for latex agglutination (1 – 2 255 
x106 CFU/ml (18)), and  similar to estimated bacterial loads of B. 256 
pseudomallei in urine (1.5 x 104 CFU/ml), sputum (1.1 x 105 CFU/ml), and pus 257 
(1.1x107 CFU/ml) samples (21). However, diagnostic sensitivity was 258 
disappointing in non-blood culture samples. We observed that viscous 259 
samples were more challenging to process for AMD and this, coupled with low 260 
initial bacterial loads, may explain the moderate sensitivity observed in these 261 
samples.  Seven pus samples in our study were received in broth from distant 262 
study sites (and therefore excluded from the main analysis) and AMD was 263 
positive in all 3 samples subsequently B. pseudomallei culture positive.  An 264 
initial enrichment culture step has been previously suggested to improve the 265 
sensitivity of IFA for B. pseudomallei from non-blood clinical samples (10). It is 266 
likely that broth incubation of pus, sputum and sterile fluid found to be AMD 267 
negative on direct testing will increase AMD sensitivity on these samples, 268 
whilst only delaying diagnosis by a few hours, although appropriate laboratory 269 
bio-safety equipment and practices would be needed.  270 
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 12 
IFA diagnostic sensitivity and specificity in this study were similar to previous 271 
reports (10). However, despite the reportedly lower LOD (2x103 CFU/ml of 272 
IFA (10), IFA was not found to be significantly more sensitive than AMD on 273 
any sample type except sterile fluids, nor was IFA significantly more specific 274 
than AMD except on pus samples. The inherent subjectivity of 275 
immunofluorescent microscopy, the difficulty of misidentifying fluorescent 276 
debris as bacteria, and the labour and resource-intensive methodology are 277 
important disadvantages of IFA compared with AMD.  278 
The number of B. pseudomallei culture-positive urine samples in this study 279 
was limited, however the ability of the AMD to detect B. pseudomallei 280 
antigenuria in melioidosis patients, particularly those with disseminated 281 
melioidosis whose urine is culture-negative for B. pseudomallei, is 282 
encouraging. Our findings replicate previous work in a non-human primate 283 
model, in which antigen was detectable in urine by AMD as early as 2-3 days 284 
after experimental infection with B. pseudomallei (D. AuCoin personal 285 
communication). The extracellular polysaccharide detected by the AMD 286 
maintains its molecular weight in urine without degradation over time which 287 
might otherwise affect the sensitivity of the AMD on urine (22). Urine is an 288 
easily available, non-invasive sample and a simple matrix for the AMD. 289 
Reliable urine antigen detection for melioidosis by a rapid test such as the 290 
AMD could revolutionize diagnostics in resource-limited parts of the world 291 
where this disease is most prevalent. However, the overall sensitivity of urine 292 
AMD for detection of melioidosis in our cohort was only 33% (37/114; 24 – 293 
41.9%). Use of simple table-top urine concentrators increased AMD sensitivity 294 
in this study, however numbers tested were limited and further work is needed 295 
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 13 
to establish the extent to which urine concentration improves AMD sensitivity 296 
in urine. At approximately $6/ sample, cost may prove a barrier to the use of 297 
this concentration technique for urine samples in endemic settings.  298 
The AMD is an extremely promising tool for diagnosis of melioidosis 299 
worldwide and meets all ASSURED criteria for RDTs (23), although further 300 
work is required to optimize sensitivity on non-blood samples. However, it is 301 
not yet a true ‘Point of Care’ test, with AMD sensitivity on stored whole blood 302 
samples from bacteraemic melioidosis patients having previously been shown 303 
to be 40% (16/40; compared with 20% sensitivity for molecular detection on 304 
the same samples) (14), and on stored serum samples in this study only 7% 305 
(5/71). The low bacterial load in blood samples (1 CFU/ml prior to broth 306 
incubation (13)) may limit the utility of the AMD on these sample types and 307 
further large-scale prospective evaluations are required.  However, the simple 308 
nature of the AMD technology means that it is more likely than molecular 309 
diagnostics to be widely applicable in a developing country context for the 310 
foreseeable future. 311 
The main limitation of this study was that not all samples underwent testing by 312 
all the relevant rapid tests. This was partly related to the nature of the study 313 
with the assays being performed during routine processing in a busy 314 
diagnostic laboratory. However, this study design gave a realistic indication of 315 
assay performance in a routine setting. In addition, the immunofluorescence 316 
assay, which had not previously been routinely used in our laboratory, took 317 
longer than expected to optimize and therefore turbid blood cultures and pus 318 
received in the initial stages of the study did not undergo IFA. Sputum and 319 
sterile fluid analyses were also limited due to low sample numbers.  320 
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 14 
In some patients in our study a positive urine AMD result was the first 321 
indication of melioidosis, preceding culture confirmation by at least 24hrs and 322 
resulting in early switch to appropriate antibiotics in critically unwell patients. 323 
This study was not designed to evaluate the clinical impact of obtaining a 324 
rapid diagnosis of melioidosis by AMD, however now that we have shown 325 
diagnostic specificity to be excellent, we are further investigating this. Throat 326 
swabs are another easily obtained sample type that is routinely used for 327 
diagnosis of melioidosis by culture in our setting. Incubation of a throat swab 328 
in liquid selective enrichment broth such as SBCT (8) would enable throat 329 
swabs to be used for rapid diagnosis of melioidosis by AMD, and this also 330 
warrants further study.  331 
In conclusion, the AMD has excellent sensitivity and specificity for early 332 
detection of B. pseudomallei in blood culture broth. It also has the advantage 333 
over the latex agglutination test that it can be used directly on other sample 334 
types for the diagnosis of melioidosis. Specificity is retained when used 335 
directly on these other samples, but sensitivity is only moderate and requires 336 
optimization. Diagnosis of melioidosis from urine using AMD may significantly 337 
enhance diagnosis of this neglected disease. Studies are needed in a variety 338 
of different prevalence settings in order to truly understand the utility of this 339 
assay, however deployment of the AMD globally could improve our 340 
understanding of the epidemiology of melioidosis. Ultimately, we hope to see 341 
LFI technology used to multiplex antigen detection for a number of important 342 
causes of febrile illness in resource-limited settings.   343 
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 15 
Materials and Methods 344 
Analytical Sensitivity and Specificity 345 
The limit of detection of the AMD was assessed using seeded blood cultures 346 
and quantitative culture techniques. A single colony of B. pseudomallei 347 
(clinical isolate) was taken from a 24-48 hour culture and a 0.5 McFarland 348 
suspension made using 5ml phosphate buffered saline (PBS). This was 349 
diluted to 1:1,000,000 and then 1 ml inoculated into each of 4 negative blood 350 
culture bottles (Pharmaceutical factory No. 2, Vientiane, Laos; (24)), shaken 351 
gently to mix and incubated aerobically at 35-37°C. From time of inoculation 352 
(Time 0) and 12 hourly thereafter blood culture broths were observed for 353 
turbidity, Gram stain was performed using standard methods, and AMD and 354 
quantitative culture were performed. AMD was performed in duplicate on 355 
paired uncentrifuged and centrifuged samples from each blood culture broth 356 
as follows: 0.5ml of blood culture broth mixture was dispensed into a 1.5ml 357 
Eppendorf tube, 1 drop of lysis buffer was added and the suspension gently 358 
mixed using a micropipette. 20µl of this suspension was then applied to the 359 
AMD test strip, followed by 3 drops of chase buffer. The result was read after 360 
15 minutes according to manufacturers instructions (Appendix 1). For 361 
centrifuged samples 1ml of blood culture broth was centrifuged at 845g 362 
(3000rpm on Microcentrifuge 5424 Eppendorf) for 10 minutes, the pellet then 363 
re-suspended in 1 drop of lysis buffer and 20µl of this suspension applied to 364 
the AMD test strip and read as above. All centrifugation was carried out in 365 
Biosafety Containment Level 3. 366 
Quantitative culture was performed using the Miles and Misra method (25): 367 
1ml was removed from each of the seeded blood culture broths after 0, 12 368 
 o
n
 M
ay 8, 2018 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://jcm.asm.org/
D
ow
nloaded from
 
 16 
and 24hrs of incubation. Each 1ml was diluted 1:10 in PBS 8 times to make 369 
dilutions of 10-1 to 10-8 concentration. 20µl of each of these dilutions was 370 
pipetted onto 1/6th of a blood agar plate, allowed to dry for 20-30 minutes, 371 
and then incubated aerobically at 35-37°C for 24hours. Each dilution was 372 
tested in triplicate. Colony-forming units/ml (CFU/ml) were calculated for each 373 
seeded blood culture as: average number of colonies for the dilution where 374 
the highest numbers of discrete colonies (between 10-100) were clearly seen 375 
x 50 x dilution factor. The result of quantitative culture was recorded and 376 
compared to AMD positivity across the panel of 4 seeded blood cultures to 377 
estimate AMD limit of detection. 378 
 379 
To investigate analytical specificity, negative blood culture broths were 380 
seeded (as above) with a range of NCTC/ATCC reference organisms 381 
(Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603, Klebsiella 382 
oxytoca NCTC 8167, Enterobacter aerogenes NCTC 10006, Enterobacter cloacae 383 
NCTC 11580, Citrobacter freundii NCTC 9750, Edwardsiella tarda NCTC 10396, 384 
Salmonella Typhi NCTC 786, Salmonella Enteritidis ATCC 13076, Pseudomonas 385 
aeruginosa ATCC 27853, Acinetobacter baumannii NCTC 12156, Ochrobactrum 386 
anthropic NCTC 12168, Aeromonas hydrophila NCTC 8049, Yersinia enterocolitica 387 
NCTC 11175, Vibrio cholera NCTC 8021, Burkholderia thailandensis NR-9908, 388 
Burkholderia cepacia NCTC 10743, Staphylococcus aureus ATCC 29213, 389 
Staphylococcus epidermidis NCTC 11047), soil isolates of Burkholderia 390 
thailandensis, and Lao clinical isolates of B. pseudomallei and B. cepacia 391 
(Table S2). Broths were incubated aerobically at 35-37°C and observed daily 392 
for turbidity. AMD was performed on uncentrifuged samples from turbid blood 393 
culture broths (as previously described).  394 
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 395 
Prospective Evaluation  396 
Study population 397 
Between 26th June and 18th December 2014 all turbid blood cultures, pus and 398 
sputum samples received at Mahosot Hospital Microbiology Laboratory, 399 
Vientiane, Laos were included. Sterile fluid samples received between 10th 400 
October and 18th December 2014 were also included. All routine urine 401 
samples received between 2nd July and 2nd September 2014 were included in 402 
order to provide baseline specificity data. After an interim analysis, selected 403 
urine samples only were included (3rd Sept – 18th December 2014 and 23rd 404 
June – 12 November 2015). Selection criteria were presence of ≥1 of the 405 
following clinical details: suspected or confirmed melioidosis; diabetes mellitus 406 
and sepsis or fever; prostatitis; lung, liver, or spleen abscess. Only the first 407 
urine sample received from a patient was included.  408 
Stored admission sera from patients diagnosed with melioidosis by culture 409 
from any sample between 26th June and 18th December 2014 were 410 
retrospectively tested by AMD in June 2015. 411 
 412 
Sample processing 413 
All samples were processed for microscopy and culture according to standard 414 
laboratory procedures (CLSI). B. pseudomallei was isolated from clinical 415 
samples using standard (goat blood, chocolate and MacConkey agars), 416 
and specific selective media (Ashdown’s agar and modified Ashdown’s 417 
selective broth (8)). Each set of blood cultures sent from a patient at any one 418 
time contained two blood-broth culture bottles (Pharmaceutical factory No. 2, 419 
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Vientiane, Laos; (24)), which were incubated aerobically at 35-37°C and 420 
observed daily for turbidity for up to 7 days. 421 
 422 
Blood cultures: AMD was performed on all turbid blood culture broths. Turbid 423 
blood cultures with Gram-negative bacilli seen on microscopy also underwent 424 
B. pseudomallei latex agglutination and immunofluorescence assay (IFA) 425 
testing. AMD method was: 0.5ml of turbid blood culture broth dispensed into a 426 
1.5ml Eppendorf tube, 1 drop of lysis buffer added and the suspension gently 427 
mixed using a micropipette. 20µl of suspension was added to 3 drops of 428 
chase buffer in a 0.6ml Eppendorf tube, and mixed by gentle pipetting. The 429 
AMD test strip was then inserted and the result read after 15 minutes 430 
according to manufacturer’s instructions (Appendix 1). Latex agglutination 431 
was performed as previously described (17): 5μl of latex reagent was mixed 432 
with one drop of uncentrifuged blood culture broth on a glass slide, gently 433 
rocked and observed for agglutination within 2 minutes. Positive (heat killed B. 434 
pseudomallei) and negative (heat killed B. thailandensis) controls were 435 
performed each day by mixing 5μl control with 5μl of latex reagent.  436 
IFA, based on the previously described method (19), was performed as 437 
follows: 10μl of turbid blood culture broth was spread on a glass slide to 438 
create a thin smear and allowed to air dry. The slide was then fixed by 439 
flooding with absolute methanol for 10 minutes at room temperature, and 440 
again allowed to air dry. 10µl of IFA reagent (containing 5µg/ml monoclonal 441 
antibody 4B11 and 20µg/ml Alexa Fluor® 488 conjugated-Goat Anti-Mouse 442 
IgG) was then applied to the smear, covered with a coverslip and incubated at 443 
room temperature for 5 minutes before observing under a fluorescent 444 
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microscope  (Nikon Eclipse E600 microscope with the U-FL Epifluorescence 445 
attachment) at a magnification of x1000 using oil immersion. Periphery of 446 
bacilli showing strong apple-green fluorescence was recorded as a positive 447 
result (10). Positive results were semi-quantified using a scheme adapted 448 
from the International Union against Tuberculosis and Lung Disease 449 
(IUATLD) guidelines for quantification of Acid Fast Bacilli (AFB) (26) (Table 450 
S3). A minimum of 100 fields were examined before slides were recorded as 451 
IFA negative (i.e. no apple-green fluorescent bacilli seen). IFA was performed 452 
on the same day that the smear was made whenever possible, and the next 453 
day if not. Slides of heat-killed (1  106 CFU/ml in PBS at 80°C for 1 hour) B. 454 
pseudomallei and B. thailandensis were used as positive and negative 455 
controls, respectively, for each batch of immunofluorescence tests. Routine 456 
laboratory staff performed the latex agglutination and AMD tests, whilst all IFA 457 
tests were performed by LB blinded to the latex and AMD test results. All 458 
blood culture work was performed in a Biosafety Cabinet at Laboratory 459 
containment level 2 according to normal local practice. 460 
 461 
Pus, sputum, sterile fluid: AMD and IFA were performed on all pus, sputum, 462 
and sterile fluid samples on receipt in the laboratory. Latex agglutination is not 463 
validated for these sample types and was therefore not performed on these 464 
samples.  IFA was performed as above using 1µl of sputum, pus or sterile 465 
fluid sample to make the original smear. AMD was performed as follows: 20µl 466 
of pus, sterile fluid or thick/viscous sputum samples was mixed with 3-4 drops 467 
of lysis buffer by vortexing for 15 seconds. 20µl of this mixture was then 468 
added to 3 drops of chase buffer in a 0.6ml Eppendorf tube and mixed by 469 
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gentle pipetting. An AMD test strip was inserted and the result read after 15 470 
minutes. Thin/watery sputum samples were processed in the same way 471 
except that 50µl of sample was mixed with 2-3 drops of lysis buffer initially. 472 
Routine laboratory staff performed AMD tests, while IFA was performed by LB 473 
blinded to the results of AMD. 474 
 475 
Urine: AMD was performed using 50µl of neat urine added to 3 drops of 476 
chase buffer in a 0.6ml Eppendorf tube and mixed by gentle pipetting. AMD 477 
test strip was then inserted and the result read after 15 minutes. AMD tests 478 
were performed by routine laboratory staff. If AMD on neat urine was negative 479 
then urine concentration was performed when concentrators (Minicon B15, 480 
Merck Millipore Ltd) were available. 5ml of urine was concentrated x100 using 481 
these simple table-top concentrators according to manufacturer’s instructions. 482 
AMD was then performed as above using 20µl of concentrated urine. Neither 483 
latex agglutination nor IFA have been validated for use directly with urine 484 
samples and were therefore not performed on these samples. 485 
 486 
Sera: Admission sera (stored at -80°C) from culture-confirmed melioidosis 487 
cases were retrieved and AMD performed as follows: 35µl serum added to the 488 
AMD test strip followed by 3 drops of Chase buffer. Results were read after 15 489 
minutes as previously. 490 
 491 
Each new box of AMD test strips underwent quality assurance by testing one 492 
strip from the box as follows: a single colony of B. pseudomallei positive 493 
control (Lao clinical isolate UI 8976) was emulsified, using a sterile loop, in 2 494 
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drops of lysis buffer. 3 drops of chase buffer were then added to this bacterial 495 
suspension and mixed gently by pipetting before the AMD test strip was 496 
inserted and read as previously described. 497 
 498 
Data Analysis 499 
Diagnostic sensitivity and specificity of the AMD, latex agglutination and IFA 500 
on the different sample types were calculated using culture as the reference 501 
standard. The sensitivity and specificity of AMD was compared with latex 502 
agglutination and IFA on turbid blood cultures containing Gram-negative 503 
bacilli, and with IFA alone for pus, sputum, and sterile fluid samples using a 504 
two-sample test of proportions. In patients confirmed with melioidosis (by 505 
culture from any sample) whose urine was culture negative for B. 506 
pseudomallei a two-sided Fisher’s exact test was used to analyze the 507 
association between urine AMD positivity and 1) disseminated vs. localized 508 
melioidosis, and 2) presence or absence of B. pseudomallei bacteraemia. 509 
Melioidosis cases were defined as ‘disseminated’ when B. pseudomallei 510 
bacteraemia was present and/or there was clinical/ radiological or 511 
microbiological evidence of multiple sites of disease. Cases were defined as 512 
‘localized’ if only one site of disease was present e.g. pneumonia or parotitis. 513 
Analysis was done using STATA, v14.2 (College Station, TX, USA).  514 
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Appendix 1. Interpretation of AMD reactivity according to 540 
manufacturer’s (InBios) instructions: 541 
 542 
C = control line; T = test line. Note a faint test line is considered positive as 543 
the red colour in this region varies depending on the concentration of antigen 544 
present. Examples of positive AMD results are given below.  545 
 546 
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Figure Legends 655 
Figure 1. Sample Flow Diagrams (“not documented” = inadequate 656 
documentation to include result in analysis; “missed” = test not performed) 657 
Figure 1a. Sample Flow diagram: Turbid blood cultures with Gram-negative 658 
bacilli seen on microscopy 659 
Figure 1b. Sample Flow diagram: Pus samples 660 
Figure 1c. Sample Flow diagram: Sputa samples 661 
Figure 1d. Sample Flow diagram: Sterile Fluid samples 662 
Figure 1e. Sample Flow diagram: Urine samples 663 
i. Urine samples - Unselected (2nd july – 2nd September 2014) 664 
ii. Urine samples – Selected (3rd Sept – 18th Dec 2014; 23rd June – 12 665 
Nov 2015) 666 
Figure 1f. Sample Flow diagram: Serum samples from culture-confirmed 667 
melioidosis cases diagnosed 26th June – 18th December 2014 668 
  669 
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Tables 670 
Table 1. Diagnostic sensitivity and specificity for all tests and sample types 671 
compared with culture as the reference standard. 672 
Specimen type 
(n) 
Test 
(n) 
Sensitivity % 
(95% Confidence Interval) 
Specificity % 
(95% Confidence Interval) 
 
Turbid Blood 
culture with 
GNB 
(252) 
AMD 
(252) 
99.0 (94.6-100%) 100 (97.6-100%) 
Latex 
(237) 
99.0 (94.5 – 100) 100 (97.4 – 100) 
IFA 
(176) 
100 (94.8 – 100) 98.1 (93.4 – 99.8) 
 p-value NS* NS** 
Pus 
(139) 
AMD 
(139) 
47.1 (23.0 - 72.2) 100 (97.0-100) 
IFA 
(95) 
66.7 (29.9 – 92.5) 90.7 (82.5-95.9) 
 p-value 0.338 0.0006 
Sputum 
(23) 
AMD 
(23) 
33.3 (0.84 – 90.6) 100 (83.2-100) 
IFA 
(23) 
100 (29.2 – 100) 85.0 (62.1-96.8) 
 p-value 0.083 0.072 
Sterile Fluid 
(46) 
AMD 
(46) 
0 (0 – 84.2%) 100 (92.0 – 100) 
IFA 
(43) 
100 (15.8 – 100) 100 (91.4-100) 
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 p-value 0.046 1.0 
Urine   
Selected 
(241) 
 
AMD 
(241) 
 
86.7 (59.5 – 98.3%) 
 
90.7 (86.2-94.2%) 
NS = not significant; * p = 0.994 for AMD v latex, 0.402 for Latex v IFA, 0.405 for IFA 673 
v AMD; ** p = 1.0 for AMD v latex, 0.107 for Latex v IFA, 0.169 for IFA v AMD  674 
 675 
  676 
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Table 2. Urine AMD results according to site of disease in melioidosis cases 677 
who were urine culture-negative for B. pseudomallei (n = 93*). 678 
Site of disease 
(n) 
Urine AMD result 
Positive Negative 
Disseminated  
(61) 
Bacteraemic (49) 15 34 
Not bacteraemic 
(12) 
3 9 
     Localized (32) 3 29 
*1 patient did not have sufficient data available to categories site of disease 679 
 680 
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